| Name | Title | Contact Details |
|---|
Signifyd was founded on the belief that e-commerce businesses should be able to grow without fear of fraud. Signifyd solves the challenges that growing e-commerce businesses persistently face: billions of dollars lost in chargebacks, customer dissatisfaction from mistaken declines, and operational costs due to tedious, manual transaction investigation. E-commerce Assurance, Signifyd`s financial guarantee protecting online retailers in case of chargebacks, is supported by a full-service cloud platform that automates fraud prevention allowing businesses to increase sales and open new markets while reducing risk. Signifyd is in use by multiple companies on the Fortune 1000 and Internet Retailer Top 500 list. Signifyd is headquartered in San Jose, CA.
RevCult helps companies break revenue records by identifying and implementing the best technology and strategies for sustainable and profitable growth. Revenue Growth Services Include: - Sales & Marketing Bottleneck Assessment - Profitable Rev...
Intrado Inc. is one of the leading providers in Software and Internet. It is based in Longmont, CO. To find more information about Intrado Inc., please visit www.intrado.com.
Descartes Labs is a predictive intelligence company that makes a data-agnostic platform for performing global-scale analyses unbound by computing limitations. Descartes Labs is building the worlds largest and most diverse data refinery - to bring together all of the data, all of the time. Our supercomputer in the cloud and modeling platform for complex global systems, predict supply and demand factors to give our customers a unique decision advantage so they can move with speed, efficiency, and certainty. Descartes Labs is headquartered in Santa Fe, N.M., and has offices in New York, San Francisco, Washington D.C., Denver, and Los Alamos, N.M.
Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.